Entia Biosciences Stock Analysis
| ERGO Stock | USD 0.0002 0.00 0.00% |
Entia Biosciences is overvalued with Real Value of 1.31E-4 and Hype Value of 1.22E-4. The main objective of Entia Biosciences pink sheet analysis is to determine its intrinsic value, which is an estimate of what Entia Biosciences is worth, separate from its market price. There are two main types of Entia Biosciences' stock analysis: fundamental analysis and technical analysis.
The Entia Biosciences pink sheet is traded in the USA on PINK Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA.
Entia |
Entia Pink Sheet Analysis Notes
The company recorded a loss per share of 0.05. Entia Biosciences had not issued any dividends in recent years. The entity had 1:10 split on the 15th of February 2012. Entia Biosciences, Inc. engages in the development, production, and distribution of dietary supplements, nutraceuticals, and medical foods products in the United States. Entia Biosciences, Inc. was founded in 2007 and is headquartered in Sherwood, Oregon. Total Nutraceutical operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 6 people.The quote for Entia Biosciences is published daily by the National Quotation Bureau and the company does not need to meet minimum requirements or file with the SEC. To learn more about Entia Biosciences call the company at 971-228-0709 or check out https://www.entiabio.com.Entia Biosciences Investment Alerts
| Entia Biosciences is way too risky over 90 days horizon | |
| Entia Biosciences has some characteristics of a very speculative penny stock | |
| Entia Biosciences appears to be risky and price may revert if volatility continues | |
| Entia Biosciences has high likelihood to experience some financial distress in the next 2 years | |
| The company has a current ratio of 0.11, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Entia Biosciences until it has trouble settling it off, either with new capital or with free cash flow. So, Entia Biosciences' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Entia Biosciences sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Entia to invest in growth at high rates of return. When we think about Entia Biosciences' use of debt, we should always consider it together with cash and equity. | |
| Entia Biosciences reported the previous year's revenue of 265.47 K. Net Loss for the year was (1.4 M) with profit before overhead, payroll, taxes, and interest of 173.97 K. | |
| Entia Biosciences currently holds about 76.05 K in cash with (715.1 K) of positive cash flow from operations. |
Entia Market Capitalization
The company currently falls under 'Nano-Cap' category with a current market capitalization of 235.63 K. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Entia Biosciences's market, we take the total number of its shares issued and multiply it by Entia Biosciences's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.Technical Drivers
As of the 12th of December 2024, Entia Biosciences shows the Mean Deviation of 2.98, variance of 151.52, and Standard Deviation of 12.31. Entia Biosciences technical analysis allows you to utilize historical prices and volume patterns in order to determine a pattern that computes the direction of the firm's future prices.Entia Biosciences Price Movement Analysis
The output start index for this execution was thirteen with a total number of output elements of fourty-eight. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Entia Biosciences middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Entia Biosciences. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
Entia Biosciences Outstanding Bonds
Entia Biosciences issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Entia Biosciences uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Entia bonds can be classified according to their maturity, which is the date when Entia Biosciences has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| MPLX LP 4875 Corp BondUS55336VAG59 | View | |
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View |
Entia Biosciences Predictive Daily Indicators
Entia Biosciences intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Entia Biosciences pink sheet daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Rate Of Daily Change | 1.0 | |||
| Day Median Price | 2.0E-4 | |||
| Day Typical Price | 2.0E-4 | |||
| Relative Strength Index | 100.0 |
Entia Biosciences Forecast Models
Entia Biosciences' time-series forecasting models are one of many Entia Biosciences' pink sheet analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Entia Biosciences' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About Entia Pink Sheet Analysis
Pink Sheet analysis is the technique used by a trader or investor to examine and evaluate how Entia Biosciences prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Entia shares will generate the highest return on investment. We also built our pink sheet analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Pink Sheet such as Entia Biosciences. By using and applying Entia Pink Sheet analysis, traders can create a robust methodology for identifying Entia entry and exit points for their positions.
Entia Biosciences, Inc. engages in the development, production, and distribution of dietary supplements, nutraceuticals, and medical foods products in the United States. Entia Biosciences, Inc. was founded in 2007 and is headquartered in Sherwood, Oregon. Total Nutraceutical operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 6 people.
Be your own money manager
As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our pink sheet analysis tools, you can find out how much better you can do when adding Entia Biosciences to your portfolios without increasing risk or reducing expected return.Did you try this?
Run Efficient Frontier Now
Efficient FrontierPlot and analyze your portfolio and positions against risk-return landscape of the market. |
| All Next | Launch Module |
Other Information on Investing in Entia Pink Sheet
Entia Biosciences financial ratios help investors to determine whether Entia Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Entia with respect to the benefits of owning Entia Biosciences security.